Microneedling for hair restoration involves daily use of a 0.3 mm device and weekly use of a 0.5 mm device. Combining microneedling with Minoxidil can enhance hair growth.
A 24-year-old person who is worried about their hair loss after 14 months of taking finasteride and 11 months of minoxidil. Replies to the post suggested sticking with their current regimen, that shedding from one part may not be telogen effluvium, and that shedding is normal with these drugs and they should evaluate in two to three months.
A user's progress in treating their hair loss using Minoxidil, Finasteride, ketoconazole shampoo, microneedling, omega 3, D3 and Forcapil vitamins over the course of three months. Other users offered support and advice to the original poster.
A user's progress with treating hair loss using 1mg finasteride per day, with reports of no noticeable side effects and positive results. Other users have shared their experiences with different treatments, such as Dutasteride and Minoxidil.
A hair transplant performed by Dr Bruno Ferreira in Portugal, which has improved the user's appearance and self-confidence. The user also mentioned taking finasteride for 5 years to help with their hair loss.
A user who shared progress pictures of their scalp using a microscope camera, demonstrating the difference between healthy and miniaturized hair. Various explanations for the cause of this were discussed, such as DHT build-up in scalp sebum causing an autoimmune response leading to inflammation and eventual hair loss, with some suggesting a do-it-yourself treatment involving adding ascorbic acid powder to shampoo.
Finasteride can cause sexual side effects in less than 2% of men, but these often disappear over time, even if the treatment continues. Some users report persistent side effects, while others experience no issues or only temporary ones.
User shared 4.5-month hair loss treatment results using Fin, Minoxidil, and microneedling. Others discussed postponing hair transplant and adjusting microneedling depth.
User experienced hair loss improvement after 7 months using finasteride, zinc, vitamin D, minoxidil, and microneedling. Others praised the progress and discussed the importance of zinc and vitamin D in hair health.
User experienced hair regrowth with minoxidil and dermarolling for 3 months. Routine includes applying 1ml minoxidil nightly and dermarolling with 0.5mm needles twice a week.
User shared 8-month hair loss treatment progress using topical fin/min, topical dut, mk677, RU, and microneedling. They experienced watery semen as a side effect but saw significant improvement in hair growth.
User shared their 14-month progress using topical Dutasteride at 0.1% for hair loss, with significant improvement and no side effects. Others discussed concerns about fertility and questioned the authenticity of the results.
A new hair loss treatment theory beyond minoxidil and finasteride is proposed, causing mixed reactions in the community, with some members eager to explore and support it, while others call for more research and evidence.
Hair loss theory involves 3alpha-hydroxysteroid reductase (3AHD) converting DHT to androstenol. Discussion explores potential treatments and encourages more research.
Topical melatonin may help reduce hair loss and increase hair thickness in people with androgenetic alopecia (AGA), with some studies showing positive results. It can be mixed with minoxidil for application, and its effectiveness might be enhanced when used with micro-needling, but results may vary among individuals.
A user who experienced hair loss at age 23, but started treatment with finasteride, minoxidil, Nizoral shampoo, dermarolling and biotin vitamins at age 32 and saw significant regrowth results in 1 year. Treatment methods such as rolling their head on the carpet were also discussed.
Minoxidil may cause wrinkles and dark circles, which some users report can be mitigated by adjusting dosage. Reactions vary, and while some dismiss these side effects, others experience significant changes.
Castor oil's effectiveness for male pattern baldness, receding hairline, and thinning crown is questioned, including its application method and potential side effects. The user also mentions experiencing hair shedding with coconut oil.
The user is struggling with hair loss and has tried treatments like finasteride, minoxidil, and hair systems, each with drawbacks. They are considering retrying finasteride before a hair transplant and are advised to seek therapy for mental health support.
A 21-year-old male with a thyroid condition noticed his hair thinning uniformly without a receding hairline. He is considering using a 5ARI to prevent further baldness if he starts TRT.
A woman who is experiencing Female Pattern Baldness and struggling to cope with it; she has tried a few treatments but is not satisfied with the results and feels like her femininity has been taken away from her. The conversation includes advice on possible treatments such as Minoxidil, Finasteride, RU58841, and lifestyle changes.
The conversation discusses the potential of topical rapamycin, metformin, and alpha-ketoglutarate (a-KG) for hair growth, with skepticism expressed about their effectiveness based on personal experience and existing use. It also mentions AICAR, known as cardarine or GW, which is not suitable for long-term use due to cancer risks in animal studies and its similarity to metformin.
The conversation discusses concerns that Anagenic's version of GT20029 might not be as effective or safe as Kintor's, with comparisons to issues faced by pyrilutamide. The chemical structure of the drug has been published.
The conversation discusses GT20029, a compound by Kintor Pharma that degrades androgen receptors and is in trials, with potential as a hair loss cure. Another promising treatment mentioned is an antibody that blocks prolactin and has shown positive results in macaques.
Amplifica is testing a compound called AMP-303 for hair loss, but it's not Scube3 or osteopontin. The timing for the results from the clinical trial is unknown.
Dr. Muñoz's discovery suggests that targeting potassium channels in fibroblasts could reactivate hair growth, offering new treatment possibilities for alopecia. Potential strategies include using minoxidil, diazoxide, and other potassium channel openers, as well as bioelectric devices and direct growth factor applications.
KX826 shows promise as a hair loss treatment with a 10% increase in hair count, but concerns about Kintor's marketing practices and the systemic effects of treatments like GT20029 and RU58841 remain. Users express skepticism and hope, with some preferring traditional treatments like finasteride and minoxidil.
RU58841, an anti-androgenic compound, showed early promise for treating alopecia but faced challenges after its patent in 1997. Despite advancing to Phase II trials, safety concerns and financial struggles led Aventis to abandon its development. Proskelia, which later merged into ProStrakan, couldn't prioritize the drug, leading to its eventual stagnation and failure to reach the market.